INFI News and Press, Infinity Pharmaceuticals Inc. From 01/07/21

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that CEO Adelene Perkins is scheduled to present virtually at three investor conferences this month. The Infinity leadership team also will be available for one-on-one meetings during the investor conferences on January 7...

Infinity Pharmaceuticals ([[INFI]] +4.8%) has provided an update on MARIO-275 Phase 2 study evaluating the benefit of adding eganelisib to Bristol-Myers' Opdivo (nivolumab) in platinum-refractory advanced urothelial cancer patients who are immuno-oncology therapy-naïve, over nivolum...

-Infinity Planning New, Registration-Enabling Study in Advanced Urothelial Cancer Leveraging Encouraging Data from MARIO-275- -MARIO-275 Data to be Presented at a Major Medical Meeting in Q1 2021- -Infinity Provides 2021 Milestones and Financial Guidance- I...

Oncternal Therapeutics (ONCT) -25% on increasing previously announced bought deal offer to $75.0M.GeoVax Labs (GOVX) -23%.Xenetic Biosciences (XBIO) -21%. on launching $6M registered direct offering priced at-the-market.Savara (SVRA) -19% on providing pipeline and business...

The following slide deck was published by Infinity Pharmaceuticals, Inc. in conjunction with this event. For further details see: Infinity Pharmaceutical (INFI) Presents at San Antonio Breast Cancer Symposium - Slideshow

Gainers: Greenwich LifeSciences (GLSI) +424%.Xenetic Biosciences (XBIO) +329%.Rocket Pharmaceuticals (RCKT) +79%.MTS Systems (MTSC) +52%.Cypress Environmental Partners (CELP) +46%.Intec Pharma (NTEC) +42%.ZW Data Action Technologies (CNET) +33%.Cardtronics (CATM) +33%.Editas Medicine (ED...

Infinity Pharmaceuticals ([[INFI]] -19.5%) has announced data from the front-line triple negative breast cancer cohort from its ongoing MARIO-3 trial, evaluating eganelisib in combination with atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane). Data were presented at the Sa...

Gainers: Xenetic Biosciences (XBIO) +410%, Greenwich LifeSciences (GLSI) +289%, Rocket Pharmaceuticals (RCKT) +74%, Intec Pharma (NTEC) +64%, ViewRay (VRAY) +14%.Losers: Atossa Therapeutics (ATOS) -39%, Pluristem Therapeutics (PSTI)&...

- 100% of Evaluable Patients Achieved Tumor Reduction Irrespective of PD-L1 Status - - 69.2% of Evaluable Patients Achieved Best Responses of Complete Response or Partial Response - - Safety Consistent With Expectations Of Component Drugs - - Conference...

Gainers: Curis (CRIS) +335%.Lexicon Pharmaceuticals (LXRX) +97%.Mammoth Energy Services (TUSK) +61%.NeuroMetrix (NURO) +49%.Stitch Fix (SFIX) +45%.IGM Biosciences (IGMS) +38%.Blonder Tongue Laboratories (BDR) +26%.Infinity Pharmaceuticals (INFI) +25%.KLX Energy Services (KLXE) +24%....